Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo

Molecular mechanisms underlying gemcitabine resistance in pancreatic cancer and restoration of sensitivity using lenalidomide.

(2017) A. G. Dalgleish et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines

(2010) Bulent Karabulut et al.   MOLECULAR BIOLOGY REPORTS

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma

(2009) V Bilim et al.   BRITISH JOURNAL OF CANCER

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

(2009) L. Escoubet-Lozach et al.   CANCER RESEARCH

Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination

(2009) Ercument Cengiz et al.   MOLECULAR BIOLOGY REPORTS

Oscillations of the p53-Akt Network: Implications on Cell Survival and Death

(2009) Keng Boon Wee et al.   PLoS One

Lenalidomide: a novel anticancer drug with multiple modalities

(2008) Christine Galustian et al.   EXPERT OPINION ON PHARMACOTHERAPY

Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors

(2008) Sharon L. Sanborn et al.   INVESTIGATIONAL NEW DRUGS

Inhibition of p38 MAPK Suppresses Inflammatory Cytokine Induction by Etoposide, 5-Fluorouracil, and Doxorubicin without Affecting Tumoricidal Activity

(2008) Collin R. Elsea et al.   PLoS One

2-Chloroadenosine modulates PAR-1 and IL-23 expression and enhances docetaxel effects on PC3 cells

(2008) Alba Minelli et al.   PROSTATE